Development and verification of a physiologically‐based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: application to prospective simulation of complex drug‐drug interaction with rivaroxaban.
British Journal of Clinical Pharmacology（2023）
摘要
Our PBPK-DDI model predicted clinically significant dronedarone-rivaroxaban DDI in both healthy and mild renal impairment subjects. Greater benefit vs. risk could be achieved with rivaroxaban dose reductions to at least 15 mg in mild renal impairment subjects on concomitant dronedarone and rivaroxaban.
更多查看译文
关键词
N-desbutyldronedarone,dronedarone,drug-drug interactions,physiologically based pharmacokinetic modelling,rivaroxaban
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要